The Growing America’s Pharmaceutical Supply (GAP Supply) Act amends two instances of the phrase "at the time" in section 503B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353b), replacing them with "within 180 calendar days." The textual edits create a defined 180‑day period tied to the statute’s timing language that governs when outsourcing facilities may compound and distribute certain drugs in the context of shortages.
This change is narrowly drafted but operationally consequential: it creates a short, statutory tail for outsourcing facilities to continue supplying a market after a drug becomes scarce. That affects how hospitals, outsourcing facilities, manufacturers, and regulators coordinate during shortages and raises practical questions about triggers, enforcement, and interactions with existing FDA shortage procedures and exclusivity incentives.
At a Glance
What It Does
The bill replaces two occurrences of the phrase "at the time" in 21 U.S.C. 353b with "within 180 calendar days," effectively authorizing a 180‑day window in which outsourcing facilities may compound and distribute certain drugs tied to the statute’s timing references. It leaves all other 503B requirements intact.
Who It Affects
Primary targets are registered outsourcing facilities operating under section 503B, hospitals and clinics that purchase compounded products, and manufacturers of drugs subject to shortage dynamics. FDA and state pharmacy regulators will also see operational impacts in oversight and monitoring.
Why It Matters
By codifying a finite tail period, the bill aims to reduce abrupt supply gaps when a marketed product becomes scarce. It shifts a timing rule in a widely used compounding statute, which can change how quickly non‑approved compounded supply enters or exits the market during shortage episodes.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Section 503B establishes a regulatory path for outsourcing facilities to compound sterile and nonsterile drugs without patient‑specific prescriptions, subject to quality and reporting obligations. The GAP Supply Act leaves that framework alone but edits two timing phrases so that the statute refers to actions taken "within 180 calendar days" instead of actions taken "at the time." Read together, those edits create a short, statutory tail during which an outsourcing facility may lawfully continue compounding and distributing a drug once the underlying timing condition (for example, the onset of a shortage) applies.
The bill does not add new reporting obligations, fees, or quality standards; it simply defines a 180‑day window tied to the statute’s timing language. In practice, outsourcing facilities would use that window to bridge supply while manufacturers respond, hospitals secure alternate products, or FDA and industry take corrective steps.
That bridging function is limited in duration and scoped to the existing 503B constraints (e.g., the requirement to register as an outsourcing facility and comply with current good manufacturing practices and adverse event reporting).Important implementation questions follow: the text does not define the precise trigger that starts the 180‑day clock (for example, FDA’s shortage designation date, a manufacturer’s market exit, or another event), nor does it state whether the window is renewable or retroactive. Because the bill leaves FDA’s broader authorities untouched, regulators would still enforce current quality, labeling, and reporting requirements and could interpret the statute in guidance or regulation.
Outsourcing facilities and purchasers will need to align operationally with whatever administrative interpretations FDA provides to avoid inadvertent noncompliance.Operationally, the change is most relevant when a marketed drug becomes scarce and immediate alternatives are limited. A short, fixed tail reduces the urgency of sudden supply cutoffs but does not substitute for durable supplier responses.
It also invites coordination problems — who manages sequencing from compounded to commercially supplied product, how payers cover the interim supply, and how liability and labeling should reflect the emergency‑driven compounding—all of which will require administrative and contract adjustments beyond the statutory text.
The Five Things You Need to Know
The bill amends two textual locations in 21 U.S.C. 353b (section 503B): subsection (a)(2)(A)(ii) and subsection (d)(2)(A).
Both edits replace the phrase "at the time" with "within 180 calendar days," creating a statutory 180‑day period tied to the statute’s timing references.
The bill does not change registration, quality, or reporting obligations for outsourcing facilities under 503B — it only modifies timing language.
The statute does not define what event starts the 180‑day period (e.g.
FDA shortage designation, market withdrawal, or another trigger), leaving that to interpretation or future FDA guidance.
No funding, enforcement penalties, or procedural changes for FDA are included; the change is textual and relies on existing FDA oversight mechanisms to be operationalized.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — 'GAP Supply Act'
This is a formal short‑title provision naming the statute the Growing America’s Pharmaceutical Supply Act or the GAP Supply Act. It has no operational effect on the substance of 503B but signals the bill’s policy intent to address pharmaceutical supply continuity and shortages.
Adds a 180‑day timing window to a subsection governing compounding activity
The bill replaces the words "at the time" with "within 180 calendar days" in subsection (a)(2)(A)(ii). That change converts a statutorily instantaneous or 'at the moment' reference into a measurable 180‑day period. Practically, this means the condition in that clause (which governs when an outsourcing facility may act under 503B) will be interpreted to permit action during the 180‑day period tied to the referenced timing event instead of only at a single point. Facilities and counsel will need to determine what administrative or factual event starts the 180‑day count.
Mirrors the same 180‑day change in the statute’s enforcement/eligibility language
The identical textual substitution appears in subsection (d)(2)(A), which addresses another timing element within 503B’s framework (often related to eligibility or exceptions). By making the same 180‑day insertion here, the bill ensures both timing references within 503B operate on the same short‑term window. Legal teams will need to reconcile how the two provisions interact operationally — for example, whether the windows run concurrently from a single trigger or separately tied to different statutory events.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Hospitals and health systems that rely on scarce sterile injectables — they gain a predictable 180‑day buffer to obtain compounded alternatives while commercial supply is restored, reducing interruption risk for critical care.
- Patients dependent on products that fall into shortage — the tail reduces the chance of immediate therapy interruption by allowing continued access to compounded supplies subject to 503B controls.
- Outsourcing facilities (503B registrants) — they receive a clear, time‑limited authorization to continue supplying a market after a timing event, enabling planning and temporary scale‑up to meet demand.
- Regional supply-chain managers and group purchasing organizations — the window allows more orderly transition plans between compounded and commercially manufactured product, potentially reducing emergency procurement costs.
Who Bears the Cost
- Brand and original manufacturers of drugs in shortage — they face increased short‑term competition from compounded supply during the 180‑day tail, which can affect revenue and incentives to restore or expand production.
- Outsourcing facilities — while they gain opportunity, they also bear added compliance costs (quality systems, documentation, stability testing) when scaling to meet shortage demand and managing the 180‑day turnover.
- FDA — the agency will shoulder interpretation, oversight, and potential enforcement workload without additional resources; it must clarify triggers and ensure quality during heightened compounding activity.
- Payers and insurers — they may encounter higher or unpredictable costs if interim compounded products have different pricing, reimbursement pathways, or require additional coverage determinations.
Key Issues
The Core Tension
The central dilemma is balancing immediate patient access against maintaining long‑term commercial incentives and quality assurance: the bill reduces short‑term supply disruption by authorizing a 180‑day compounding tail, but doing so risks weakening manufacturers’ market signals to restore supply and places additional oversight burdens on FDA and outsourcing facilities without changing quality standards or enforcement resources.
The bill is tightly focused on timing language, which keeps it legally tidy but pushes hard, practical questions to regulators and implementers. The single most important implementation issue is the start‑date ambiguity: the statute uses the 180‑day phrase but does not say when the clock starts.
Reasonable candidates include the date FDA publicly lists a shortage, the date a manufacturer notifies FDA of discontinuation, or the date the outsourcing facility becomes aware of the shortage — each choice has different incentives and operational consequences. Without a clear trigger, stakeholders face legal and supply‑chain uncertainty.
Another trade‑off is between short‑term supply resilience and market incentives. A fixed 180‑day tail helps prevent abrupt patient harm by permitting compounded supply, but it may blunt commercial firms’ urgency to restore production if compounded products supplant some market share temporarily.
Quality oversight is the other unresolved area: the bill leaves existing 503B quality and reporting rules unchanged, but surges in compounding volume during the tail will strain inspection, testing, and adverse‑event surveillance systems. Those systems will need administrative guidance and possibly resources to function effectively under the new cadence.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.